Abstract
The innominate artery is a predilection site for atherosclerotic lesion formation in hyperlipidemic mice. The lesions at this site in chow-fed apo E-/- mice progress from fatty streaks through stages that include atheroma with large necrotic areas, fibro-fatty nodules containing chondrocyte-like cells and highly calcified, acellular plaques. The advanced lesions in the innominate arteries of the apo E-/- mice exhibit a reproducible frequency of intra-plaque hemorrhage that occurs primarily as a result of fissures through lateral fatty streaks that form adjacent to or on top of the established plaques. However, this plaque disruption is not equivalent to plaque rupture in human lesions where there is rupture of well formed fibrous caps. The plaque disruption in the lesions of the chow-fed apo E-/- mice also do not lead to formation of occlusive thrombi, the predominant marker of plaque rupture in humans. Thus, although the lesions in the innominate arteries of hyperlipidemic mice progress to very advanced stages of the disease, they are not, in our opinion a model in which to study the mechanisms of plaque rupture in humans. The advanced lesions in the innominate arteries of the apo E-/- mice may however be adequate models for studying vascular fibrosis and calcification.
Current Drug Targets
Title: Progression and Disruption of Advanced Atherosclerotic Plaques in Murine Models
Volume: 9 Issue: 3
Author(s): Michael E. Rosenfeld, Michelle M. Averill, Brian J. Bennett and Stephen M. Schwartz
Affiliation:
Abstract: The innominate artery is a predilection site for atherosclerotic lesion formation in hyperlipidemic mice. The lesions at this site in chow-fed apo E-/- mice progress from fatty streaks through stages that include atheroma with large necrotic areas, fibro-fatty nodules containing chondrocyte-like cells and highly calcified, acellular plaques. The advanced lesions in the innominate arteries of the apo E-/- mice exhibit a reproducible frequency of intra-plaque hemorrhage that occurs primarily as a result of fissures through lateral fatty streaks that form adjacent to or on top of the established plaques. However, this plaque disruption is not equivalent to plaque rupture in human lesions where there is rupture of well formed fibrous caps. The plaque disruption in the lesions of the chow-fed apo E-/- mice also do not lead to formation of occlusive thrombi, the predominant marker of plaque rupture in humans. Thus, although the lesions in the innominate arteries of hyperlipidemic mice progress to very advanced stages of the disease, they are not, in our opinion a model in which to study the mechanisms of plaque rupture in humans. The advanced lesions in the innominate arteries of the apo E-/- mice may however be adequate models for studying vascular fibrosis and calcification.
Export Options
About this article
Cite this article as:
Rosenfeld E. Michael, Averill M. Michelle, Bennett J. Brian and Schwartz M. Stephen, Progression and Disruption of Advanced Atherosclerotic Plaques in Murine Models, Current Drug Targets 2008; 9 (3) . https://dx.doi.org/10.2174/138945008783755575
DOI https://dx.doi.org/10.2174/138945008783755575 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Current Vascular Pharmacology Role of Statins in Peri-Operative Medicine
Current Drug Targets Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Extracellular Hsp70: Export and Function
Current Protein & Peptide Science Calcium Channel Blockade and Peroxisome Proliferator Activated Receptor γ Agonism Diminish Cognitive Loss and Preserve Endothelial Function During Diabetes Mellitus
Current Neurovascular Research Drug Eluting Stents for Vulnerable Plague
Current Pharmaceutical Design Contribution of Mast Cells to Cerebral Aneurysm Formation
Current Neurovascular Research New therapeutic effects of cilostazol in patients with ischemic disorders
Current Vascular Pharmacology Endovascular Versus Open Abdominal Aortic Aneurysm: Best Decision
Current Pharmaceutical Design Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology Should We be Concerned About the Inflammatory Response to Endovascular Procedures?
Current Vascular Pharmacology Contrast-induced Nephropathy in Non-cardiac Vascular Procedures, A Narrative Review: Part 1
Current Vascular Pharmacology Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology Statin Use in Aortic Aneurismal Disease to Prevent Progression and Cardiovascular Events: Review of Experimental and Clinical Data
Current Vascular Pharmacology Anesthetic and Adjunctive Drugs for Fast-Track Surgery
Current Drug Targets Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Diabetes as a Negative Risk Factor for Abdominal Aortic Aneurysm – Does the Disease Aetiology or the Treatment Provide the Mechanism of Protection?
Current Vascular Pharmacology Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews All for Statins and Statins for All; An Update
Current Pharmaceutical Design